Zhuonan Ran1, Jiexing Liu1, Fen Wang2, Caiyan Xin2, Xiang Shen1, Shan Zeng1, Zhangyong Song2,3, Bin Xiong1. 1. The Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China. 2. Department of Pathogenic Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China. 3. Molecular Biotechnology Platform, Public Center of Experimental Technology, Southwest Medical University, Luzhou 646000, China.
Abstract
BACKGROUND: The pulmonary microbiome is closely related to the occurrence of pulmonary diseases. The morbidity and mortality of lung cancer are relatively high in the world. It has been confirmed that lung microecology changes in lung cancer patients compared with healthy individuals. Furthermore, the abundance of some bacterial species shows obvious changes, suggesting their potential use as a microbial marker for the detection of lung cancer. The composition of the pulmonary microbiome in patients with different histological types of lung cancer has not been determined. We aim to study the correlation and difference of microbiome between different histological types of lung cancer. METHODS: Illumina HiSeq high-throughput sequencing technology was used to sequenced the 16S rDNA V3-V4 region of bacterial in sputum samples of patients with advanced lung cancer. RESULTS: It was found that Streptococcus, Neisseria and Prevotella were the main bacteria of lung cancer patients. Advantage bacterium group differ between different histological types of lung cancer. Adenocarcinoma (AD) group was dominated by Streptococcus and Neisseria, followed by Veillonella. Small cell lung cancer (SCLC) group was dominated by Neisseria, followed by Streptococcus. Squamous carcinoma (SCC) group was dominated by Streptococcus, followed by Veillonella. Combined small cell lung cancer (C-SCLC) group was dominated by Streptococcus, followed by Prevotella. CONCLUSIONS: The pulmonary bacterial microbiome of lung cancer of different histological types is different. This experiment enrichs the pulmonary bacterial microbiome data of lung cancer and fills the gap of pulmonary microbiome of small cell lung cancer.
BACKGROUND: The pulmonary microbiome is closely related to the occurrence of pulmonary diseases. The morbidity and mortality of lung cancer are relatively high in the world. It has been confirmed that lung microecology changes in lung cancerpatients compared with healthy individuals. Furthermore, the abundance of some bacterial species shows obvious changes, suggesting their potential use as a microbial marker for the detection of lung cancer. The composition of the pulmonary microbiome in patients with different histological types of lung cancer has not been determined. We aim to study the correlation and difference of microbiome between different histological types of lung cancer. METHODS: Illumina HiSeq high-throughput sequencing technology was used to sequenced the 16S rDNA V3-V4 region of bacterial in sputum samples of patients with advanced lung cancer. RESULTS: It was found that Streptococcus, Neisseria and Prevotella were the main bacteria of lung cancerpatients. Advantage bacterium group differ between different histological types of lung cancer. Adenocarcinoma (AD) group was dominated by Streptococcus and Neisseria, followed by Veillonella. Small cell lung cancer (SCLC) group was dominated by Neisseria, followed by Streptococcus. Squamous carcinoma (SCC) group was dominated by Streptococcus, followed by Veillonella. Combined small cell lung cancer (C-SCLC) group was dominated by Streptococcus, followed by Prevotella. CONCLUSIONS: The pulmonary bacterial microbiome of lung cancer of different histological types is different. This experiment enrichs the pulmonary bacterial microbiome data of lung cancer and fills the gap of pulmonary microbiome of small cell lung cancer.
Authors: Kurtis F Budden; Shakti D Shukla; Saima Firdous Rehman; Kate L Bowerman; Simon Keely; Philip Hugenholtz; Darius P H Armstrong-James; Ian M Adcock; Sanjay H Chotirmall; Kian Fan Chung; Philip M Hansbro Journal: Lancet Respir Med Date: 2019-04-08 Impact factor: 30.700
Authors: John R Erb-Downward; Deborah L Thompson; Meilan K Han; Christine M Freeman; Lisa McCloskey; Lindsay A Schmidt; Vincent B Young; Galen B Toews; Jeffrey L Curtis; Baskaran Sundaram; Fernando J Martinez; Gary B Huffnagle Journal: PLoS One Date: 2011-02-22 Impact factor: 3.240
Authors: Marta Di Pasquale; Stefano Aliberti; Chara Azzari; Maria Moriondo; Francesco Nieddu; Francesco Blasi; Marco Mantero Journal: SAGE Open Med Date: 2017-07-16
Authors: Simon J S Cameron; Keir E Lewis; Sharon A Huws; Matthew J Hegarty; Paul D Lewis; Justin A Pachebat; Luis A J Mur Journal: PLoS One Date: 2017-05-25 Impact factor: 3.240
Authors: Robert P Dickson; John R Erb-Downward; Christine M Freeman; Lisa McCloskey; Nicole R Falkowski; Gary B Huffnagle; Jeffrey L Curtis Journal: mBio Date: 2017-02-14 Impact factor: 7.867
Authors: Vladimir G Druzhinin; Elizaveta D Baranova; Ludmila V Matskova; Pavel S Demenkov; Valentin P Volobaev; Varvara I Minina; Alexey V Larionov; Snezana A Paradnikova Journal: Life (Basel) Date: 2022-06-02